Corbus Pharmaceuticals Holdings Inc. [NASDAQ: CRBP] closed the trading session at $1.83 on 04/07/21. The day’s price range saw the stock hit a low of $1.74, while the highest price level was $1.91. The company report on March 30, 2021 that Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis.
Topline data on schedule for Q2 2021.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Dermatomyositis is a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, and affects ~80,000 people in North America, EU, and Japan.
The stocks have a year to date performance of 46.40 percent and weekly performance of -1.08 percent. The stock has been moved at -3.17 percent over the last six months. The stock has performed -1.61 percent around the most recent 30 days and changed 28.87 percent over the most recent 3-months.
If compared to the average trading volume of 14.60M shares, CRBP reached to a volume of 4858355 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Corbus Pharmaceuticals Holdings Inc. [CRBP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRBP shares is $2.23 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRBP stock is a recommendation set at 2.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH Capital have made an estimate for Corbus Pharmaceuticals Holdings Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 08, 2020. The new note on the price target was released on September 08, 2020, representing the official price target for Corbus Pharmaceuticals Holdings Inc. stock. Previously, the target price had yet another drop from $18 to $2.50, while Jefferies kept a Hold rating on CRBP stock.
The Average True Range (ATR) for Corbus Pharmaceuticals Holdings Inc. is set at 0.20, with the Price to Sales ratio for CRBP stock in the period of the last 12 months amounting to 56.33. The Price to Book ratio for the last quarter was 3.52, with the Price to Cash per share for the same quarter was set at 0.71.
CRBP stock trade performance evaluation
Corbus Pharmaceuticals Holdings Inc. [CRBP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.08. With this latest performance, CRBP shares dropped by -1.61% in over the last four-week period, additionally sinking by -3.17% over the last 6 months – not to mention a drop of -64.74% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRBP stock in for the last two-week period is set at 39.73, with the RSI for the last a single of trading hit 36.41, and the three-weeks RSI is set at 42.64 for Corbus Pharmaceuticals Holdings Inc. [CRBP]. The present Moving Average for the last 50 days of trading for this stock 2.3283, while it was recorded at 1.9380 for the last single week of trading, and 3.3167 for the last 200 days.
Corbus Pharmaceuticals Holdings Inc. [CRBP]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Corbus Pharmaceuticals Holdings Inc. [CRBP] shares currently have an operating margin of -3119.20. Corbus Pharmaceuticals Holdings Inc.’s Net Margin is presently recorded at -2826.08.
Return on Total Capital for CRBP is now -280.02, given the latest momentum, and Return on Invested Capital for the company is -262.89. Return on Equity for this stock declined to -432.68, with Return on Assets sitting at -146.95. When it comes to the capital structure of this company, Corbus Pharmaceuticals Holdings Inc. [CRBP] has a Total Debt to Total Equity ratio set at 59.27. Additionally, CRBP Total Debt to Total Capital is recorded at 37.22, with Total Debt to Total Assets ending up at 26.23. Long-Term Debt to Equity for the company is recorded at 55.49, with the Long-Term Debt to Total Capital now at 34.84.
Reflecting on the efficiency of the workforce at the company, Corbus Pharmaceuticals Holdings Inc. [CRBP] managed to generate an average of -$1,464,071 per employee. Receivables Turnover for the company is 1.50 with a Total Asset Turnover recorded at a value of 0.05.Corbus Pharmaceuticals Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.90 and a Current Ratio set at 2.90.
Earnings per share (EPS) analysis for Corbus Pharmaceuticals Holdings Inc. [CRBP] stock
With the latest financial reports released by the company, Corbus Pharmaceuticals Holdings Inc. posted -0.43/share EPS, while the average EPS was predicted by analysts to be reported at -0.4/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -7.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRBP.
Corbus Pharmaceuticals Holdings Inc. [CRBP]: Insider Ownership positions
There are presently around $72 million, or 33.40% of CRBP stock, in the hands of institutional investors. The top three institutional holders of CRBP stocks are: ETF MANAGERS GROUP, LLC with ownership of 8,103,641, which is approximately 122.039% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 5,220,525 shares of the stock with an approximate value of $9.55 million in CRBP stocks shares; and KNOLL CAPITAL MANAGEMENT, LP, currently with $9.23 million in CRBP stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Corbus Pharmaceuticals Holdings Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 44 institutional holders increased their position in Corbus Pharmaceuticals Holdings Inc. [NASDAQ:CRBP] by around 8,055,016 shares. Additionally, 74 investors decreased positions by around 25,093,512 shares, while 22 investors held positions by with 6,215,891 shares. The mentioned changes placed institutional holdings at 39,364,419 shares, according to the latest SEC report filing. CRBP stock had 23 new institutional investments in for a total of 817,290 shares, while 32 institutional investors sold positions of 4,257,392 shares during the same period.